Submission based on positive data from the Phase 3 ADAPT-SC trial demonstrating noninferiority of subcutaneous (SC) efgartigimod compared to intravenously administered VYVGART® (efgartigimod alfa-fcab) based on total immunoglobulin G (IgG) reduction at day 29
https://finance.yahoo.com/news/argenx-submits-biologics-license-application-050000853.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.